Volume 11, Number 12—December 2005
Research
Porcine Noroviruses Related to Human Noroviruses
Qiu-Hong Wang*, Myung Guk Han*, Sonia Cheetham*, Menira Souza*, Julie A. Funk†, and Kwonil Jung*
Table 4
Antigenic cross-reactivity between human GII NoV antigens (VLPs) and a pig convalescent-phase antiserum against porcine GII NoVs, as determined by ELISA*
| Antiserum | ELISA antibody titer with each VLP antigen (genogroup-genotype) |
|||||
|---|---|---|---|---|---|---|
| Hawaii (GII-1) | Toronto (GII-3) | MD145 (GII-4) | HS66 (GII-4) | Florida (GII-6) | Desert Shield (GI-3) | |
| HS66CS (positive control): human convalescent antiserum to human HS66 (GII-4) | 1:25,600 | 1:6,400 | 1:25,600 | 1:25,600 | 1:6,400 | 1:6,400 |
| LL616: pig convalescent-phase antiserum to porcine QW126 (QW101-like, GII-18)† | 1:100 | 1:800 | 1:400 | 1:400 | 1:400 | 1:10 |
| LL368 (negative control): preinoculation serum‡ | <1:10 | <1:10 | <1:10 | <1:10 | <1:10 | <1:10 |
| MM982 (negative control): preinoculation serum‡ | <1:10 | <1:10 | <1:10 | <1:10 | <1:10 | <1:10 |
*NoV, norovirus; VLP, viruslike particle; ELISA, enzyme-linked immunosorbent assay.
†The QW126 shared 99% and 100% amino acid identities to the QW101 strain (GII-18) for a 169-bp segment in the RNA-dependent RNA polymerase region and a 363-bp segment in the capsid region, respectively.
‡LL368 and MM982 were sera from 2 gnotobiotic pigs before inoculation with porcine NoVs.
Page created: February 02, 2012
Page updated: February 02, 2012
Page reviewed: February 02, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential